Crinetics Pharmaceuticals (CRNX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$1.14
- Estimate
- -$1.18
- Surprise
- +3.7%
- Revenue (period 2026-06-30)
- $25.1M
- Score today
- 4.5/10
Revenue source: xbrl.
How the report landed
Crinetics Pharmaceuticals (CRNX) reported a narrower loss than forecast — diluted EPS of -$1.14 against the -$1.18 estimate (a 3.7% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CRNX Sell at 4.5/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +3.7% surprise compares with a -1.0% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Product: PALSONIFY (paltusotine)
- Target reached (-12.9% upside)
- Quality below floor (1.9 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $84.97
- Price target
- $97.69
- Stop
- $84.69
- Upside to target
- +15.0%
Risk check: RSI 86 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 3.2× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
CRNX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $9.01B
- P/E (fwd)
- -20.6
- 52-week range
- $32.30–$85.01
- Off 52-week high
- 0.0%
- RSI (14)
- 86
- Volume vs avg
- 3.20×
- Score today
- 4.5/10